TECX EBITDA | TECTONIC THERAPEUTIC, INC.

TECTONIC THERAPEUTIC, INC. (TECX) EBITDA

2026-06-30: Basis Reported; EBITDA -$23.93M*; Operating income -$24.22M; Depreciation and amortization $285.00K*.
2026-03-31: Basis Reported; EBITDA -$27M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$21.18M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$21.55M*; Operating income -$21.89M; Depreciation and amortization $342.00K*.

Complete source-backed ebitda history.

Available history: 2017-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$23.93M*	-$24.22M	$285.00K*	(m)	(m)	$79.00K*	-$21.45M*	(m)	$18.05M	(m)	$77.00K
2026-03-31	Reported	-$27M	(m)	(m)	(m)	(m)	$19.00K	-$18.41M	(m)	$20.87M	(m)	(m)
2025-12-31	Reported	-$21.18M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$21.55M*	-$21.89M	$342.00K*	(m)	(m)	$181.00K*	-$17.82M*	(m)	$16.93M	(m)	$0.00
2025-06-30	Reported	-$21.99M*	-$22.33M	$340.00K*	(m)	(m)	$0.00*	-$14.72M*	(m)	$17.18M	(m)	$976.00K
2025-03-31	Reported	-$17.94M	(m)	(m)	(m)	(m)	$27.00K	-$13.08M	(m)	$13.04M	(m)	(m)
2024-12-31	Reported	-$13.48M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$19.21M*	-$19.64M	$424.00K*	(m)	(m)	$153.00K*	-$19.60M*	(m)	$14.32M	$0.00*	$0.00
2024-06-30	Reported	-$11.09M*	-$11.42M	$336.00K*	(m)	(m)	-$4.00K*	-$13.38M*	(m)	$7.07M	$9.90M	$0.00
2024-03-31	Reported	-$12.59M	(m)	(m)	(m)	(m)	$4.00K	-$9.27M	(m)	$10.82M	(m)	(m)
2023-12-31	Reported	-$9M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$9.74M*	-$10.11M	$371.00K*	(m)	(m)	$7.00K*	-$8.48M*	(m)	$8.13M	(m)	$0.00
2023-06-30	Reported	-$10.34M	(m)	(m)	(m)	(m)	$214.00K*	-$259.00K*	(m)	$8.77M	(m)	$0.00
2023-03-31	Reported	-$24.89M	(m)	(m)	(m)	(m)	$8.00K	-$20.28M	(m)	$17.33M	(m)	(m)
2022-12-31	Reported	-$24.92M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$22.65M	(m)	(m)	(m)	(m)	$86.00K*	-$16.41M*	(m)	$15.92M	(m)	(m)
2022-06-30	Reported	-$27.42M	(m)	(m)	(m)	(m)	$149.00K*	-$29.11M*	(m)	$18.88M	(m)	(m)
2022-03-31	Reported	-$29.02M	(m)	(m)	(m)	(m)	$32.00K	-$28.01M	(m)	$19.25M	(m)	(m)
2021-12-31	Reported	-$27.53M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$32.25M	(m)	(m)	(m)	(m)	$267.00K*	-$24.82M*	(m)	$23.04M	(m)	(m)
2021-06-30	Reported	-$31.08M	(m)	(m)	(m)	(m)	$1.23M*	-$19.96M*	(m)	$22.54M	(m)	(m)
2021-03-31	Reported	-$26.59M	(m)	(m)	(m)	(m)	$115.00K	-$27.34M	(m)	$18.53M	(m)	(m)
2020-12-31	Reported	-$27.76M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$36.42M	(m)	(m)	(m)	(m)	$31.00K*	-$24.86M*	(m)	$28.51M	(m)	(m)
2020-06-30	Reported	-$28.56M	(m)	(m)	(m)	(m)	$488.00K*	-$21.02M*	(m)	$20.87M	(m)	(m)
2020-03-31	Reported	-$26.31M	(m)	(m)	(m)	(m)	$577.00K	-$22.43M	(m)	$18.27M	(m)	(m)
2019-12-31	Reported	-$23.19M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$17.85M	(m)	(m)	(m)	(m)	$78.00K*	-$13.38M*	(m)	$13.04M	(m)	(m)
2019-06-30	Reported	-$16.41M*	-$16.61M	$200.00K*	(m)	(m)	$401.00K*	-$17.96M*	(m)	$12.27M	(m)	(m)
2019-03-31	Reported	-$17.51M	(m)	(m)	(m)	(m)	$340.00K	-$17.74M	(m)	$12.45M	(m)	(m)
2018-12-31	Reported	-$16.49M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	(m)	-$12.23M	(m)	(m)	(m)	(m)	(m)	(m)	$9.23M	(m)	(m)
2018-09-30	Reported	-$12.10M*	-$12.23M	$130.00K*	(m)	(m)	$915.00K*	-$11.98M*	(m)	$9.23M	(m)	(m)
2018-06-30	Reported	-$9.50M*	-$9.55M	$45.00K*	(m)	(m)	$161.00K*	-$8.25M*	(m)	$7.41M	(m)	(m)
2018-03-31	Reported	-$7.77M	(m)	(m)	(m)	(m)	$263.00K	-$5.98M	(m)	$5.65M	(m)	(m)
2017-12-31	Reported	-$7.41M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$6.37M	(m)	(m)	(m)	(m)	(m)	(m)	$5.41M	(m)	(m)
2017-06-30	Reported	(m)	-$2.54M	(m)	(m)	(m)	(m)	(m)	(m)	$1.88M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$82.66M	(m)	(m)	(m)	(m)	$208.00K	-$60.08M	(m)	$63.49M	(m)	$1.23M
2024-12-31	Reported	-$56.37M	(m)	(m)	(m)	(m)	$156.00K	-$59.08M	(m)	$41.36M	(m)	$0.00
2023-12-31	Reported	-$43.17M	(m)	(m)	(m)	(m)	$279.00K	-$40.68M	(m)	$36.97M	(m)	$0.00
2022-12-31	Reported	-$103.99M	(m)	(m)	(m)	(m)	$267.00K	-$97.21M	(m)	$72.19M	(m)	$0.00
2021-12-31	Reported	-$117.44M	(m)	(m)	(m)	(m)	$2.46M	-$98.03M	(m)	$83.11M	(m)	(m)
2020-12-31	Reported	-$119.02M	(m)	(m)	(m)	(m)	$1.18M	-$98.80M	(m)	$87.24M	(m)	(m)
2019-12-31	Reported	-$74.96M	(m)	(m)	(m)	(m)	$1.58M	-$67.67M	(m)	$54.97M	(m)	(m)
2018-12-31	Reported	-$45.86M	(m)	(m)	(m)	(m)	$1.83M	-$37.65M	(m)	$35.09M	(m)	(m)
2017-12-31	Reported	-$18.34M	(m)	(m)	(m)	(m)	$383.00K	-$16.38M	(m)	$15.19M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
REGENXBIO Inc. (RGNX)	United States	$0.477B	-3.30
Entera Bio Ltd. (ENTX)		$0.485B
Eikon Therapeutics, Inc. (EIKN)	United States	$0.446B
Kyverna Therapeutics, Inc. (KYTX)	United States	$0.434B	-3.60
Autolus Therapeutics plc (AUTL)		$0.506B	-1.52
Editas Medicine, Inc. (EDIT)	United States	$0.424B	-4.29
Scribe Therapeutics, Inc. (SCTX)	United States	$0.410B
Zura Bio Ltd (ZURA)		$0.398B	-6.56
Surrozen, Inc./DE (SRZN)	United States	$0.395B
AGENUS INC (AGEN)	United States	$0.383B	1.41